Datapoint: FDA Expands Otezla’s Psoriasis Label

The FDA last month expanded the patient population of Amgen Inc.’s Otezla (apremilast) to include the treatment of people between 6 and 17 years old and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. The agency first approved the phosphodiesterase 4 (PDE4) inhibitor on March 21, 2014. Dosing for the new patient population of the tablet is 30 mg twice daily for people weighing at least 50 kg; for those at least 20 kg and less than 50 kg, dosing is 20 mg twice daily. For the treatment of psoriasis, virtually all insured lives have covered or better access to Otezla. 48% of covered lives have preferred access to Otezla, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 5/13/24

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 12

Datapoint: Centene to Expand Cityblock Partnership to Florida

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 11

Datapoint: SCAN Wins Stars Challenge Against CMS

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 10

Datapoint: Blue Cross and Blue Shield of Kansas City to Exit MA Market

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today